

APPLIED GENETIC TECHNOLOGIES CORP
Form 8-K
March 02, 2018

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): February 28, 2018

APPLIED GENETIC TECHNOLOGIES CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or other jurisdiction

of incorporation)

001-36370
(Commission

File Number)
14193 NW 119th Terrace

59-3553710
(IRS Employer

Identification Number)

Suite 10

Alachua, Florida, 32165

(Address of principal executive offices) (Zip Code)

(386) 462-2204

(Registrant's telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below).

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: APPLIED GENETIC TECHNOLOGIES CORP - Form 8-K

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 5.07.Submission of Matters to a Vote of Security Holders.

We held our 2018 Annual Meeting of Stockholders on February 28, 2018, at which two proposals were submitted to, and approved by, our stockholders. The holders of 13,154,284 shares of our common stock were present or represented by proxy at the meeting. The proposals are described in detail in our definitive proxy statement for the 2018 Annual Meeting filed with the Securities and Exchange Commission on January 29, 2018. The final results for the votes for each proposal are set forth below.

At the annual meeting, Anne VanLent was elected as a Class I Director of the Company, to serve a three-year term expiring at the 2021 Annual Meeting of Stockholders. The votes cast in the election of the director were as follows:

Nominee	Votes For	Votes Withheld	Broker Non-Votes
Anne VanLent	4,744,440	3,615,768	4,794,076

At the annual meeting, our stockholders also approved the proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending on June 30, 2018. The votes cast on this proposal were as follows:

Proposal	Votes For	Votes Against	Abstentions	Broker Non-Votes
To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for fiscal year 2018	13,112,626	38,564	3,094	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

**APPLIED GENETIC TECHNOLOGIES
CORPORATION**

By: /s/ Andrew Ashe
Andrew Ashe
General Counsel

Date: March 2, 2018